Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Asahi Kasei Sees Healthcare as Core "High Growth Business"
July 31, 2006
- R&D NEWS IN BRIEF
July 31, 2006
- Original Clarithromycin Tastes Better than Generics: Taisho Toyama
July 31, 2006
- Drug Development Beyond Borders -Today's Global Cooperative Clinical Trials- Part III: Pfizer's Views
July 31, 2006
- Acquisition of Schering AG Should Boost Profitability: Bayer Yakuhin
July 31, 2006
- Novo Nordisk Pharma to Cover GP Market in Future
July 31, 2006
- 3rd Science and Technology Forum
July 31, 2006
- Chugai to Market Modified Version of Tamiflu in Japan
July 31, 2006
- World's 1st Transdermal Agent for AD under Development by Novartis
July 31, 2006
- Anti-Parkinson's Drug KW-6002 Expected to Become Major Product: Kyowa Hakko
July 31, 2006
- SELF-MEDICATION NEWS IN BRIEF
July 31, 2006
- Covance Dedicates Itself to Development Service
July 31, 2006
- REGULATORY NEWS IN BRIEF
July 31, 2006
- MEDICAL DEVICE NEWS IN BRIEF
July 31, 2006
- JPMA Petition Calls For Increases in PMDA Reviewers
July 31, 2006
- SEMINAR
July 31, 2006
- Anact C's Approval Recommended for Purpura Fulminans
July 31, 2006
- Japanese Breast Cancer Society Drug Treatment Guidelines Amended
July 31, 2006
- COMMENTARY an article
July 31, 2006
- Arteriosclerosis Treatment GL under Amendment
July 31, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…